Compare PESI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | ENLV |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 196.2M |
| IPO Year | 1996 | 2014 |
| Metric | PESI | ENLV |
|---|---|---|
| Price | $9.81 | $0.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 282.6K | ★ 344.9K |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $34.62 | N/A |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.14 | $0.66 |
| 52 Week High | $16.50 | $2.10 |
| Indicator | PESI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 59.70 |
| Support Level | $9.82 | $0.77 |
| Resistance Level | $12.33 | $1.23 |
| Average True Range (ATR) | 0.68 | 0.05 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 54.12 | 99.41 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.